Lantern Pharma Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Lantern Pharma Inc
Did you know?
Capital expenditures decreased by 86% from FY24 to FY25.
Current Price
$2.23
+5.19%Profile
Valuation (TTM)
Market Cap$24.94M
P/E-1.46
EV—
P/B3.82
Shares Out11.18M
P/Sales—
Revenue$0.00
EV/EBITDA—
Lantern Pharma Inc (LTRN) Stock Analysis
Market Cap$24.94M
Current Price$2.23
P/E Ratio-1.46
Forward P/E—
PEG Ratio0.04
EPS$-1.57
Book Value$0.58
P/B Ratio3.82
LTRN Financial Charts
FCF vs CAPEX
FCFCAPEX
Cash vs Debt
Net Cash: 4M
Revenue
—
FY19
—
FY20
—
FY21
—
FY22
—
FY23
—
FY24
—
FY25
Net Income
—
FY19
—
FY20
—
FY21
—
FY22
—
FY23
—
FY24
—
FY25
LTRN 52-Week Range
$1.12
$5.32
50-Day MA: $2.29200-Day MA: $3.42
Did you know?
Price sits at 26% of its 52-week range.
Lantern Pharma Inc (LTRN) Financial Summary
Lantern Pharma Inc (LTRN) is a Healthcare company in the Biotechnology industry, listed on NASDAQ. The stock currently trades at $2.23 with a market capitalization of $24.94M.
Key valuation metrics include a P/E ratio of -1.46, price-to-book ratio of 3.82, and EPS of $-1.57. and return on equity of -262.0%.
LTRN Key Financial Metrics
| Metric | Value |
|---|---|
| Market Cap | $24.94M |
| P/E Ratio | -1.46 |
| EPS | $-1.57 |
| P/B Ratio | 3.82 |
| Return on Equity | -262.0% |
| Debt/Equity | 0.01 |
LTRN Revenue & Earnings History
| Year | Revenue | Net Income |
|---|---|---|
| FY19 | $0.00 | $-2.43M |
| FY20 | $0.00 | $-5.91M |
| FY21 | $0.00 | $-12.36M |
| FY22 | $0.00 | $-14.26M |
| FY23 | $0.00 | $-15.96M |
| FY24 | $0.00 | $-20.78M |
| FY25 | $0.00 | $-17.12M |
About Lantern Pharma Inc
Lantern Pharma Inc
LTRN Free Cash Flow
Lantern Pharma Inc generated $-15.68M in trailing twelve-month free cash flow, representing an FCF yield of -62.86%. This low FCF yield may reflect heavy reinvestment or growth spending.
LTRN Shares Outstanding
Lantern Pharma Inc has 0.01 billion shares outstanding at a share price of $2.23, giving it a market capitalization of $24.94M.